Lyra in Action
At Lyra, we are advancing leading-edge science to develop therapeutics that can make a positive impact on the lives of millions of patients.
Here are some of the ways we are making a difference for patients, for new therapeutic products, and for our community.
Lyra CMO Robert Kern, MD, discusses the positive LANTERN Phase 2 study results for LYR-210, offering hope for a new treatment option with up to 6 months of relief for Chronic Rhinosinusitis patients.
Drug Delivery Business took a dive into Lyra’s product approach for chronic rhinosinusitis, LYR-210 and the company’s platform for ENT and other chronic diseases.
On the MassDevice list of “8 drug delivery innovations you need to know,” Lyra was recognized as “looking to make waves in the ear, nose and throat (otolaryngology) disease treatment space with drugs administered through a bioresorbable polymeric matrix.”
We are pleased to welcome our new CMO, Robert Kern, MD, a renowned physician in the ENT field and a world-leading expert in chronic rhinosinusitis. Introduced in this Drug Delivery Business News article, Dr. Kern will oversee the development of Lyra’s clinical pipeline.
Lyra CEO MariaPalasis was elected into the National Academy of Engineering for outstanding contributions to the design of medical devices and drug delivery systems, including her work on LYR-210 and LYR-220.
Lyra CEO Maria Palasis hosted two networking sessions on Combination Products at the MedExecWomen Fall Forum, focused on advances in medtech and medical devices by women leaders.
Lyra is pleased to welcome Dr. Nancy Snyderman to the Board of Directors. An accomplished otolaryngologist and surgeon, she brings deep expertise that will be invaluable as we advance innovative treatments for ear, nose and throat diseases.
How can companies add more women in leadership roles? How can women pursue these positions? In a Q&A, CEO Maria Palasis discusses specific steps both can take to increase gender diversity in the workplace.
Lyra CEO Maria Palasis was one of three women leaders in life sciences discussing the current unique capital raising environment on a panel hosted by BioDirector.
The Lyra team participated in the Nasdaq virtual opening bell ringing ceremony to commemorate the company’s first week on the Nasdaq exchange as LYRA.
Our CEO Maria Palasis discusses connecting technology innovation with patient needs and shares advice for anyone pursuing a career in biotechnology in this interview in The Medicine Maker
We are pleased to welcome our new CFO, R. Don Elsey, profiled in this WSJ.com CFO Journal article, to help Lyra develop into a commercially focused company as our lead drug candidate, LYR-210, enters a Phase 2 clinical trial for the treatment of chronic rhinosinusitis.
International Forum of Allergy & Rhinology, April 2019
Editorial by David W. Kennedy, M.D.
Douglas et al. report on a phase 1 clinical study of a novel biodegradable mometasone furoate drug delivery system for treating CRS in the unoperated patient. This is the first steroid-eluting implant intended for use in patients who have not had prior surgery, and elutes the steroid over a 24-week period.
Lyra supports a diverse workplace and celebrates the company’s women executives and managers on International Women’s Day. We are proud to have our CEO Maria Palasis as a frequent speaker on the topic of women in science and industry.
Working with a team of researchers with global expertise, Lyra and Richard Douglas, M.D., Professor of Surgery at The University of Auckland, New Zealand, and Consultant Surgeon at Auckland City Hospital, publish Phase 1 clinical data for the company’s lead therapeutic, LYR210, for chronic rhinosinusitis (CRS), in the International Forum of Allergy & Rhinology [Publication]
